BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

838 related articles for article (PubMed ID: 26848860)

  • 21. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
    Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
    Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.
    Mitra P; Eckenrode JM; Mandal A; Jha AK; Salem SM; Leggas M; Rohr J
    J Med Chem; 2018 Sep; 61(17):8001-8016. PubMed ID: 30114371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
    Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
    Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromatin profiling reveals relocalization of lysine-specific demethylase 1 by an oncogenic fusion protein.
    Theisen ER; Selich-Anderson J; Miller KR; Tanner JM; Taslim C; Pishas KI; Sharma S; Lessnick SL
    Epigenetics; 2021 Apr; 16(4):405-424. PubMed ID: 32842875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma.
    Tokarsky EJ; Crow JC; Guenther LM; Sherman J; Taslim C; Alexe G; Pishas KI; Rask G; Justis BS; Kasumova A; Stegmaier K; Lessnick SL; Theisen ER
    Mol Cancer Res; 2022 Jul; 20(7):1035-1046. PubMed ID: 35298000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
    Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
    Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone.
    Park H; Turkalo TK; Nelson K; Folmsbee SS; Robb C; Roper B; Azuma M
    Cell Cycle; 2014; 13(15):2391-9. PubMed ID: 25483190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of EWS/FLI-1 fusion in non-Ewing soft tissue tumors.
    Trancău IO; Huică R; Surcel M; Munteanu A; Ursaciuc C
    J Med Life; 2015; 8(1):85-9. PubMed ID: 25914746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma.
    Showpnil IA; Selich-Anderson J; Taslim C; Boone MA; Crow JC; Theisen ER; Lessnick SL
    Nucleic Acids Res; 2022 Sep; 50(17):9814-9837. PubMed ID: 36124657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
    Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
    Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
    Yuan B; Ji W; Xia H; Li J
    Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
    Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
    PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
    Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
    Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
    Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
    Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.
    Castillero-Trejo Y; Eliazer S; Xiang L; Richardson JA; Ilaria RL
    Cancer Res; 2005 Oct; 65(19):8698-705. PubMed ID: 16204038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma.
    Chaturvedi A; Hoffman LM; Jensen CC; Lin YC; Grossmann AH; Randall RL; Lessnick SL; Welm AL; Beckerle MC
    Mol Biol Cell; 2014 Sep; 25(18):2695-709. PubMed ID: 25057021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.